Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia

AIMS: This population pharmacokinetic analysis was conducted to describe quantitatively the regional differences and sources of interpatient variability on the apparent oral clearance of alisertib. METHODS: A population pharmacokinetic analysis was performed on data from 671 cancer patients in Weste...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiaofei, Mould, Diane R., Takubo, Takatoshi, Sheldon‐Waniga, Emily, Huebner, Dirk, Milton, Ashley, Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736852/
https://www.ncbi.nlm.nih.gov/pubmed/28891222
http://dx.doi.org/10.1111/bcp.13430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736852/
https://www.ncbi.nlm.nih.gov/pubmed/28891222
http://dx.doi.org/10.1111/bcp.13430

Ejemplares similares